John Newcomer, MD

An Assessment of the Impact of Prior Antipsychotic Treatment on the Duration of Treatment with RBP-7000 during a Long-Term Safety Study

Introduction: RBP-7000 (PERSERIS™) is a once-monthly subcutaneous extended-release risperidone formulation approved for the treatment of schizophrenia in adults, designed to deliver clini...

Anne Andorn , MD;

James Graham , PharmD, BS Pharm, RPh;

Maurizio Fava , MD, PhD;

John Csernansky , MD;

John Newcomer , MD;

Anne Le Moigne , PhD;

10/08/2020

Lurasidone and Metabolic Syndrome: Results From Short- and Long-Term Clinical Studies in Patients With Bipolar Depression

Background: The elevated prevalence of metabolic syndrome (MetS) in patients with depression has been associated with increased mortality rates. The aim of this post-hoc analysis was to a...

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Yongcai Mao , PhD;

John Newcomer , MD;

11/22/2019

Efficacy of Monthly Extended-release Risperidone Injections (RBP-7000) for the Treatment of Schizophrenia: An Analysis of Individual PANSS Items

Introduction: RBP-7000 (PERSERIS™) is a once-monthly, subcutaneous, extended-release risperidone formulation that is approved for treating schizophrenia in adults and is designed to deliv...

Anne Andorn , MD;

James Graham , PharmD, BS Pharm, RPh;

Maurizio Fava , MD, PhD;

John Csernansky , MD;

John Newcomer , MD;

Sunita Shinde , MD;

Gilbert Muma , PhD;

Christian Heidbreder , PhD;

David Walling , PhD, CNS, MD;

11/22/2019

Insulin Sensitivity and Glucose Metabolism of Olanzapine and Combination Olanzapine and Samidorphan: A Phase 1 Exploratory Study in Healthy Volunteers

Background: A combination of olanzapine and samidorphan (OLZ/SAM) is in development for schizophrenia to provide the efficacy of olanzapine while mitigating olanzapine-associated weight g...

Mark Namchuck , PhD;

John Newcomer , MD;

David McDonnell , MD;

Ying Jiang , PhD;

Christine Graham , PhD;

Linda Morrow , MD;

Carine Beysen , DPhil;

Frederico Toledo , MD;

Daiva Bajorunas , MD;

Bernard Silverman , MD;

11/22/2019

RBP-7000 for the Treatment of Schizophrenia: Efficacy and Safety Results From Two Phase III Trials

Introduction: RBP-7000 is a subcutaneously administered, once-monthly, extended-release depot formulation of risperidone designed to achieve therapeutic concentrations without supplementa...

Anne Andorn , MD;

Maurizio Fava , MD, PhD;

John Newcomer , MD;

Sunita Shinde , MD;

Gilbert Muma , PhD;

Christian Heidbreder , PhD;

Jay Graham , BS Pharm, PharmD, RPh;

03/01/2019